Findings are based on a retrospective, multicenter study carried out in Spain.
New research details the long-term safety and efficacy of secukinumab in bio-naïve patients with moderate to severe cutaneous psoriasis.
Writing in Journal of the European Academy of Dermatology and Venerology, study authors explained, “the high efficacy and long-term survival rates observed and the low prevalence of arthritis and comorbidities might suggest that early intervention could contribute to modify the course of the disease, but further studies are needed.”
Secukinumab is a monoclonal antibody that neutralizes interleukin-17A. Previous studies have found the treatment is effective and safe in patients with psoriatic arthritis and pustular, erythrodermic and moderate to severe cutaneous psoriasis.
However, real-world studies on the long-term efficacy and survival in bio-naïve patients are limited, the present study authors said. To address this knowledge gap, they conducted a retrospective, multicenter study in a Spanish cohort of patients with psoriasis. All included patients were naïve to biological therapies and followed for up to 8 years.
Participants were recruited from 8 Spanish hospitals between January 2014 and January 2022. At baseline, patients received 300 mg of secukinumab weekly during the first 4 weeks and then on a monthly basis. During the follow-up period, some went on to receive an intensified or optimized regimen.
Researchers monitored the cohort at baseline; weeks 4, 12, and 24; and every 12 plus or minus 4 weeks until week 416. There were 128 patients included in the study.
Analyses revealed these findings:
The mean (SD) patient age was 50.9 (13.95) years, and 18.8% of participants had psoriatic arthritis. In addition, nearly 30% had arterial hypertension, 15% had diabetes, and 35% had dyslipidemia.
Forty-seven percent of participants were obese, and the mean duration of psoriasis prior to treatment was 16.1 (11.8) years. Most patients (92.2%) also had classical psoriasis plaques.
The current study marks one of the largest multicentric long-term cohort reports on real-world experience of secukinumab in bio-naïve psoriatic patients, the authors said.
The overall efficacy in bio-naïve patients reported was similar to that observed in previous reports, they added.
“In our study, both secukinumab response and drug survival in nonbiologic-experienced patients were found to be independent of weight, age, sex, and the presence of psoriatic arthritis, in contrast with some previously reported series, which also included biological-experienced subjects, [that] could explain these facts,” the researchers explained.
The low incidence of psoriatic arthritis, diabetes, and cardiac failure in the current analysis may reinforce theories claiming early intensive treatment with secukinumab might modify the natural course of the disease and even prevent psoriatic arthritis development or psoriasis-related comorbidities.
The absence of a control group and the study’s retrospective design mark limitations. Some baseline characteristics were also not fully documented.
“As observed in our cohort, the high long-term efficacy and survival of secukinumab in bio-naïve patients and the low prevalence of arthritis and psoriasis-related comorbidities might suggest that managing severe psoriasis as a systemic disease, introducing advanced treatments early, could potentially modify the march of this disease, but further studies are needed,” the authors concluded.
Reference
Ramos FJM, Puchades AM, Climent SG, et al. Long-term secukinumab efficacy and safety in bio-naïve patients with moderate-to-severe cutaneous psoriasis: a real-world retrospective noninterventional multicentric experience (128 patients). J Eur Acad Dermatol Venereol. Published online May 27, 2023. doi:10.1002/jvc2.185
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With Advanced, Recurrent Melanoma May Experience Lasting AEs From ICM Therapy
May 9th 2024A cross-sectional, mixed-methods study found that adverse effects (AEs) can occur even after 1 year of treatment with immune checkpoint modulator (ICM) therapy in patients with melanoma.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Goal Achievement in T1D Management Boosts Self-Efficacy, Self-Care Among Emerging Adults
May 9th 2024Findings from the FAMS-T1D study demonstrate that structured goal-setting and achievement significantly enhance self-efficacy and self-care in emerging adults who have type 1 diabetes (T1D).
Read More
Medication Adherence Star Ratings Measures, Health Care Resource Utilization, and Cost
May 9th 2024For patients prescribed diabetes, hypertension, and hyperlipidemia medications, nonadherence to CMS Star Ratings quality measures of medication adherence was associated with increased health care resource utilization and costs.
Read More